Expression of p170 protein in multiple myeloma: A clinical study

G. Ucci, M. Petrini, A. Riccardi, R. Invernizzi, G. Carulli, R. Luoni, M. Giordano, M. Danova

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The expression of the p170 multidrug resistance protein by bone marrow plasma cells (BMPC) was assessed at clinical presentation in 53 patients with multiple myeloma (MM) using the C219 monoclonal antibody. Twenty-two of the 53 (41 per cent) patients had variable aliquots (1-60 per cent, median = 6 per cent) of p170 + BMPC by immunocytochemistry. Five of 10 patients studied using bivariate flow cytometry had both diploid and hyperdiploid (DNA index ranged from 1.2 to 1.5) BMPC with hyperdiploid clones having significantly greater p170 expression than diploid ones. Of the 37 patients evaluated for a response, 20 (54 per cent) had responded to induction chemotherapy. The presence of p170 + BMPC was a negative indicator for achieving response. The response rate was 75 per cent for p170- and 25 per cent for p170+ cases (p <0.01), with no difference on the basis of treatment schedule (melphalan and prednisone, 24 patients; peptichemio, vincristine and prednisone, 13 patients). No difference in response and survival duration was found between p170+ and p170- patients. In six of nine patients studied both at diagnosis and folllowing induction chemotherapy the p170+ BMPC% increased irrespective of the type of treatment or outcome.

Original languageEnglish
Pages (from-to)213-220
Number of pages8
JournalHematological Oncology
Volume10
Issue number3-4
DOIs
Publication statusPublished - 1992

Fingerprint

Multiple Myeloma
Plasma Cells
Bone Marrow Cells
Proteins
Induction Chemotherapy
Polyploidy
Prednisone
Diploidy
Peptichemio
P-Glycoproteins
Melphalan
Clinical Studies
Vincristine
Appointments and Schedules
Flow Cytometry
Clone Cells
Immunohistochemistry
Monoclonal Antibodies
Survival
DNA

Keywords

  • Myeloma
  • p170
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Expression of p170 protein in multiple myeloma : A clinical study. / Ucci, G.; Petrini, M.; Riccardi, A.; Invernizzi, R.; Carulli, G.; Luoni, R.; Giordano, M.; Danova, M.

In: Hematological Oncology, Vol. 10, No. 3-4, 1992, p. 213-220.

Research output: Contribution to journalArticle

Ucci, G, Petrini, M, Riccardi, A, Invernizzi, R, Carulli, G, Luoni, R, Giordano, M & Danova, M 1992, 'Expression of p170 protein in multiple myeloma: A clinical study', Hematological Oncology, vol. 10, no. 3-4, pp. 213-220. https://doi.org/10.1002/hon.2900100312
Ucci, G. ; Petrini, M. ; Riccardi, A. ; Invernizzi, R. ; Carulli, G. ; Luoni, R. ; Giordano, M. ; Danova, M. / Expression of p170 protein in multiple myeloma : A clinical study. In: Hematological Oncology. 1992 ; Vol. 10, No. 3-4. pp. 213-220.
@article{163da5e9d0fe4d18945b447090964d3c,
title = "Expression of p170 protein in multiple myeloma: A clinical study",
abstract = "The expression of the p170 multidrug resistance protein by bone marrow plasma cells (BMPC) was assessed at clinical presentation in 53 patients with multiple myeloma (MM) using the C219 monoclonal antibody. Twenty-two of the 53 (41 per cent) patients had variable aliquots (1-60 per cent, median = 6 per cent) of p170 + BMPC by immunocytochemistry. Five of 10 patients studied using bivariate flow cytometry had both diploid and hyperdiploid (DNA index ranged from 1.2 to 1.5) BMPC with hyperdiploid clones having significantly greater p170 expression than diploid ones. Of the 37 patients evaluated for a response, 20 (54 per cent) had responded to induction chemotherapy. The presence of p170 + BMPC was a negative indicator for achieving response. The response rate was 75 per cent for p170- and 25 per cent for p170+ cases (p <0.01), with no difference on the basis of treatment schedule (melphalan and prednisone, 24 patients; peptichemio, vincristine and prednisone, 13 patients). No difference in response and survival duration was found between p170+ and p170- patients. In six of nine patients studied both at diagnosis and folllowing induction chemotherapy the p170+ BMPC{\%} increased irrespective of the type of treatment or outcome.",
keywords = "Myeloma, p170, Therapy",
author = "G. Ucci and M. Petrini and A. Riccardi and R. Invernizzi and G. Carulli and R. Luoni and M. Giordano and M. Danova",
year = "1992",
doi = "10.1002/hon.2900100312",
language = "English",
volume = "10",
pages = "213--220",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "3-4",

}

TY - JOUR

T1 - Expression of p170 protein in multiple myeloma

T2 - A clinical study

AU - Ucci, G.

AU - Petrini, M.

AU - Riccardi, A.

AU - Invernizzi, R.

AU - Carulli, G.

AU - Luoni, R.

AU - Giordano, M.

AU - Danova, M.

PY - 1992

Y1 - 1992

N2 - The expression of the p170 multidrug resistance protein by bone marrow plasma cells (BMPC) was assessed at clinical presentation in 53 patients with multiple myeloma (MM) using the C219 monoclonal antibody. Twenty-two of the 53 (41 per cent) patients had variable aliquots (1-60 per cent, median = 6 per cent) of p170 + BMPC by immunocytochemistry. Five of 10 patients studied using bivariate flow cytometry had both diploid and hyperdiploid (DNA index ranged from 1.2 to 1.5) BMPC with hyperdiploid clones having significantly greater p170 expression than diploid ones. Of the 37 patients evaluated for a response, 20 (54 per cent) had responded to induction chemotherapy. The presence of p170 + BMPC was a negative indicator for achieving response. The response rate was 75 per cent for p170- and 25 per cent for p170+ cases (p <0.01), with no difference on the basis of treatment schedule (melphalan and prednisone, 24 patients; peptichemio, vincristine and prednisone, 13 patients). No difference in response and survival duration was found between p170+ and p170- patients. In six of nine patients studied both at diagnosis and folllowing induction chemotherapy the p170+ BMPC% increased irrespective of the type of treatment or outcome.

AB - The expression of the p170 multidrug resistance protein by bone marrow plasma cells (BMPC) was assessed at clinical presentation in 53 patients with multiple myeloma (MM) using the C219 monoclonal antibody. Twenty-two of the 53 (41 per cent) patients had variable aliquots (1-60 per cent, median = 6 per cent) of p170 + BMPC by immunocytochemistry. Five of 10 patients studied using bivariate flow cytometry had both diploid and hyperdiploid (DNA index ranged from 1.2 to 1.5) BMPC with hyperdiploid clones having significantly greater p170 expression than diploid ones. Of the 37 patients evaluated for a response, 20 (54 per cent) had responded to induction chemotherapy. The presence of p170 + BMPC was a negative indicator for achieving response. The response rate was 75 per cent for p170- and 25 per cent for p170+ cases (p <0.01), with no difference on the basis of treatment schedule (melphalan and prednisone, 24 patients; peptichemio, vincristine and prednisone, 13 patients). No difference in response and survival duration was found between p170+ and p170- patients. In six of nine patients studied both at diagnosis and folllowing induction chemotherapy the p170+ BMPC% increased irrespective of the type of treatment or outcome.

KW - Myeloma

KW - p170

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0026743233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026743233&partnerID=8YFLogxK

U2 - 10.1002/hon.2900100312

DO - 10.1002/hon.2900100312

M3 - Article

C2 - 1356905

AN - SCOPUS:0026743233

VL - 10

SP - 213

EP - 220

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 3-4

ER -